BACKGROUND: Many aspects of transfusion medicine are affected by genetics. Current single-nucleotide polymorphism (SNP) arrays are limited in the number of targets that can be interrogated and cannot detect all variation of interest. We designed a transfusion medicine array (TM-Array) for study of both common and rare transfusion-relevant variations in genetically diverse donor and recipient populations.
therapeutic apheresis, stem cell collections, cellular therapy, and hemostasis. Genetics play a central role in transfusion research and transfusion practice. [1] [2] [3] The early discovery of human blood groups, particularly the ABO and Rh systems, [4] [5] [6] [7] and the recognition of the need to ensure compatibility between donors and recipients has led to a high degree of safety such that blood transfusions became one of the most common medical procedures. In contrast, despite the early discovery of key genes and mutations causal to hemoglobinopathies, hemochromatosis, thrombosis, and coagulation, [8] [9] [10] [11] genome-wide understanding of the effects of genetics on many other aspects of transfusion medicine practice, such as storage hemolysis and posttransfusion reactions, is lacking. Genome-wide association studies (GWASs) simultaneously test for associations between phenotypic variables and millions of genetic markers. 12, 13 GWASs have been applied to numerous hematologic endpoints and have advanced our knowledge of the genetic underpinnings of modifiers of complete blood count, hematopoiesis, cardiovascular diseases, and sickle cell anemia. [14] [15] [16] [17] [18] Transplant research has benefitted from GWASs by identifying novel genes and alleles that are associated with kidney transplant rejection and clinical outcomes in patients with renal and lung transplants. [19] [20] [21] [22] [23] [24] Although advances in whole genome sequencing have made it possible to interrogate causal variants directly as opposed to evaluating variants that are in linkage disequilibrium with causal variants, 25 array-based genotyping remains a cost-effective method for genotyping large cohorts, such as the UK Biobank cohort, in which half a million participants have been enrolled and genotyped. 26 Additionally, conducting array-based GWASs on samples prior to whole genome sequencing or whole exome sequencing is of value for detecting gender mismatches, sample swaps, and relatedness in the study population. Array-based genotyping is highly compatible with whole exome sequencing/whole genome sequencing to ensure concordance and fidelity especially in high-priority regions of the genome. Modern genetics will continue to play a critical role in blood donor safety and transfusion outcome research and practices. 27, 28 A customized Affymetrix Axiom genome-wide single-nucleotide polymorphism (SNP) array, called the transfusion medicine array (TM-Array), was developed to facilitate transfusion genetics research. It was developed with two goals in mind: 1) to allow the genome-wide study of genetically diverse populations, and 2) to study transfusion medicine-specific variants and genes in detail. The TM-Array includes genes involved in red blood cell (RBC) and platelet structure and function, human leukocyte antigen (HLA), blood groups including human platelet antigen, iron metabolism, sickle cell trait, glucose-6-phosphatedehydrogenase deficiency, pica, and restless leg syndrome, among others. SNPs were selected to be informative in diverse populations. The array has been used to genotype nearly 16,000 participants: 13,168 blood donors enrolled in the National Heart, Lung, and Blood Institute (NHLBI) 
METHODS
The Affymetrix axiom genotyping platform
The Affymetrix Axiom platform is a hybridization-based genotyping array that offers a flexible choice of predesigned modules and customizable contents. Its utility has been shown in large cohorts, such as the UK Biobank 26 and Million
Veteran Program, 29 multirace/ethnic cohorts, 30 and in focused research areas such as transplant research. 24 There are approximately 1.38 million features available. Some SNPs and copy number polymorphisms (CNPs) take more than one feature to be genotyped with high quality. As a result, the TM-Array contains approximately 879,000 SNPs and CNPs.
TM array design and variant selection
The TM-Array's core imputation sets of SNPs was built starting with the UK Biobank Array European GWAS grid content and supplemented with SNPs to increase coverage in Eastern Asians, African Americans, and Brazilians with the aim of providing near full genome imputed coverage down to minor allele frequency (MAF) of 5% in European, African, and East Asian populations. In addition to the core genome-wide imputation grid, the design included customized transfusion medicine content. Experts in the areas of RBCs, platelets, blood groups, iron metabolism, SCD, pica, restless leg syndrome, and other hematologic disorders recommended the addition of relevant genes and genetic variation. Extensive bioinformatics mining of resources such as PubMed, Genotype-Tissue Expression project, 31 and the GWA SNP catalog 13 was performed. Additionally, we drew on the Affymetrix catalog of variation and existing arrays such as the transplant array. 24 The design is detailed below and illustrated in Fig. 1 .
Genome-wide coverage module (approximately 559,000 markers)
The genome-wide coverage module consists of three main components: African American and East Asian GWAS boosters were designed to provide over 90% imputation coverage for common variants (MAF ≥5%).
Affymetrix commercial modules
Predesigned module contents were added to the design to capture markers identified based on currently identified GWAS signals, targeted regions, pharmacokinetics, and pharmacology-relevant signals. This consists of the following six modules: All known blood systems, including ABO, Rh, and 32 additional blood group loci were considered in the design of this array. SNPs and insertion/deletions (indels) were initially extracted from two sources: (1) the latest (third edition) AABB standards for accreditation of laboratories testing for blood groups, platelet, and neutrophil antigens by DNA 32 ; and (2) the European Bioinformatics Institute Immuno Polymorphism-human platelet antigens database. 33 The lists were further expanded using the blood group antigen gene mutation (BGMUT) database. 34, 35 The BGMUT database documented 1777 alleles associated with blood group phenotypes. We extracted all nucleotide changes for these alleles and mapped them to human genome (GRCh37) chromosome and position location whenever possible. This list consists of 729 SNPs and 2 CNPs (the 37 bp indel defining the RHD pseudogene and the 109 bp indel defining RHC/c). Bioinformatics mining and comprehensive literature review were performed for variants and genes associated with hemolysis [search term "(hemolysis) AND (SNP OR polymorphism OR variant) AND (association OR associated)"; 222 results], iron disorders [search term "iron AND disorder AND (SNP OR polymorphism OR variant) AND (association OR associated)"; 422 results) and various specific blood-and iron-related disorders. Examples of blood disorder queries include anemia, leukemia, clotting, and bleeding. Examples of iron disorder queries include hemochromatosis, restless leg syndrome, atherosclerosis, metabolic syndrome, and liver disease; 3,885 variants and 141 genes associated with these disorders were extracted from research articles and reviews. The list of genes was further appended by adding 936 proximal genes.
A search of relevant genetic modulators of inflammation included cytokines, chemokines, interleukins, interferons, growth factors, tumor necrosis factor superfamily, antiinflammatory cytokines, and their receptors. Additional comprehensive literature review was performed by searching PubMed using query "(coagulation OR cytokines) AND platelet AND (SNP OR polymorphism OR variant) AND (association OR associated)" (search date 10/19/2015; 256 results).
This list was further augmented by genes that encode for proteins previously detected in proteomics studies of red blood cells 36 and platelets (33 studies aggregated in Thomas et al. 37 ), as well proteins in the cell-scale metabolic networks for those cells. 37, 38 Additional blood group variants and SCD genes manually curated by the expert panel were appended to the lists. In summary, prior to the design of the genome-wide booster grid, we included 145 transplant-relevant SNPs, 13 restless leg syndrome SNPs, 3885 SNPs in blood and iron disorder genes, 729 SNPs in blood group genes, 125 SNPs in coagulation and cytokine genes, and all 34,000 SNPs previously associated with a disorder in a GWAS. After the design achieved the desired genome-wide coverage by including the genome-wide booster modules, the array was filled by SNPs down to 1% in gene regions of 141 iron-related genes, 3856 megakaryocytes and platelets proteins, 1285 genes with the corresponding proteins known to occur in or on the red cells, 238 cytokine genes, 155 transforming growth factor genes, and 48 SCD-related genes. We tiled the alpha globin, beta globin, and RHD/RHCE loci with approximately 1000 SNPs to allow the detection of copy number changes.
These lists have overlap with each other, and some trimming was performed on loci in high linkage disequilibrium. In total, the TM-Array includes 879,348 SNPs and CNPs (Fig. 1 ).
Study populations
The major goal of the NHLBI REDS-III multicenter program is to conduct research that advances blood storage and TM practices and outcomes. One of the REDS-III components, referred to as the RBC-Omics study, enrolled 13,403 blood donors from many races/ethnicities. 39, 40 The study characterized fresh blood from the donated blood units (using complete blood count and ferritin assays) and end of storage (i.e., approx. 42-day stored) leukoreduced RBC componentderived samples derived from their blood donation (using spontaneous and stress hemolysis assays). While recruitment targeted high-intensity donors and minority populations, including Asian, African American, and Hispanic donors, the US donor population most closely resembles this study population. Additionally, REDS-III has also conducted a cohort study of 2798 patients with SCD from six hemocenters in Brazil who are being followed longitudinally. 41 High-quality DNA was obtained from both cohorts using white blood cells (WBCs) eluted from leukoreduced filters for the RBC-Omics study and whole blood samples for the Brazil SCD cohort.
RESULTS

Genotyping quality control
A total of 16,417 samples (13,168 of 13,403 blood donors, 2700 of 2798 patients with SCD, 36 biological replicates, and control samples including those from the 1000 Genomes Project 42 were run on the TM-Array generating 14,436,256,116 genotypes. On average, more than 99.2% of biallelic markers were successfully called as high-resolution SNPs using the Affymetrix Axiom analysis pipeline. Only a few samples (<0.5%) were called with less than 95% of markers ( Table 1 ). The quality of genotypes was assessed by calling them twice using different permutations of sample batches. Inconsistent genotype calls were present in 0.08% of highquality markers, of which 97.6% were no-call versus call. Only 5704 markers (0.7%) showed inconsistencies among five or more people. These markers were excluded from subsequent evaluation. Further examination of genotype calling metrics using SNPolisher off-target variant (OTV) caller 43 revealed that the cluster plots provided good cluster (Table 2B) .
Reproducibility evaluation
Within-array reproducibility DNA extraction and genotyping were conducted twice on 36 subjects to evaluate the performance of the array and the reproducibility of genotype calling. For a single SNP, genotype calls were deemed as mismatch if the call results differed between the two replicates and neither genotyping resulted in no call. The median mismatch rate among the 36 replications was 0.029% (range, 0.013%-0.37%; 29 of the 36 samples lower than 0.1%). Additionally, the rate of difference between no call and call in the replicated samples was low (median rate, 0.41%, 3366 markers; 28 of the 36 samples lower than 1%).
Mendelian error checking
One trio from the 1000 Genomes Project (HG00418, HG00419, HG00420) and four retrospectively genetically identified RBC-Omics trios were used to assess Mendelian error rates. On average, fewer than 200 (0.024%) Mendelian errors were identified in each trio. A total of 1306 (0.16%) markers failed Mendelian checking in any trios.
Marker-based CNP calling for D antigen
The Rh blood group system contains many antigens. The D-negative phenotype when it occurs in a European population most often results from the homozygous deletion of the RHD gene, although other mutations are also known. Traditionally, it has been hard to tag the deletion directly using marker-based techniques. Therefore, determination of D-negative status by DNA-based methods includes the use of SNP markers that are in linkage disequilibrium with this deletion or the use of polymerase chain reactionbased methods. [45] [46] [47] In the TM-Array, probes were designed specifically for typing the deletion. Approximately 17% of Dnegative participants were observed in the RBC-Omics population, a close resemblance of the US donation population. Furthermore, the typing method achieved 99.6% accuracy compared to serology testing (Fig. 2) . Thus, the TM-Array represents a potential low-cost, high-throughput D typing method.
Blood typing variant assessment
More than 700 variants are documented in the BGMUT database for 33 blood group systems. 34, 35 Blood donors enrolled in the RBC-Omics study had serologic ABO typing and D typing available. Numerous other serology typing results were available for the Brazil SCD cohort patients. High concordance (98.18%) was observed comparing genetically inferred ABO typing based on the five most informative variants (c.261delG, 467C > T, 703G > A, 802G > A, 1096G > A) to the serology testing results (Table 3) . Allele frequencies are close to the expected population frequency for Brazilian and US donor populations for blood group markers (Table 4 ). Even though rare variants are hard to call due to the lack of rare homozygotes or heterozygotes around which to base a cluster, variants with low (<1%) MAF on the TM-Array were genotyped and clustered well, assessed based on clustering statistics and congruency with expected population frequencies (Table 4) . A full list of blood group variants included in the array design are documented in Table S1 , available as supporting information in the online version of this paper.
Sickle cell anemia variants assessment
A total of 12 pairs of probes were designed to capture HbS and HbC alleles, which are 1 bp apart (rs334, chr11:5227002, T = sickle S; rs33930165, chr11:5227003, A = sickle C). A supervised clustering method with cross validation resulted in an approximately 96% concordance rate within the Brazil SCD population. An unsupervised k-means clustering method with K = 3 applied to genotype calling and signal intensity data resulted in an approximately 93% concordance rate compared to clinical diagnosis. An example probe intensity plot is shown in Fig. S1 , available as supporting information in the online version of this paper. The supervised clustering model was applied to RBC-Omics to predict the population prevalence of sickle cell trait (person who carries an HbS mutation) in the United States.
Approximately 0.69% of the RBC-Omics participants carry a sickle cell trait.
DISCUSSION
A TM-Array for transfusion medicine discovery research has been tailor-made following extensive literature review, consultation with transfusion experts, and bioinformatics mining. The array includes transfusion medicine-relevant variants with low MAF (<5%). This overcomes a major limitation of array-based SNP assays, which is the limited number of variants an array can contain; thus, rare or uncommon variants or multiple markers needed for comprehensive determination of, for example, ABO and RH are not well covered. GWAS-based discovery of a causal variant not directly represented on the array is made by association of markers in linkage disequilibrium (LD) with the causal variant and the phenotype of interest. This imputation not only reduces statistical power to detect the variant, but also biases analyses toward identification of causal variants with small effect size that are in high LD with markers on the array, versus causal variants with large effect size but in low LD with markers on the array. 48 The design of the TM-Array puts emphasis on transfusion medicine-relevant genetics and provides dense variant coverage down to MAF of 1% in transfusion medicinerelevant gene regions such as blood group genes (e.g., ABO, MNS, and RHD/RHCE). For example, KEL 578 T > C (rs8176058) associates with the Kell system K+/− phenotype. However, because of the low T allele frequency (approx. 0.006), this SNP is omitted in most genome-wide genotyping arrays, and cannot be imputed accurately for the same reason. Another example is the sickle cell HbS mutation (rs334), whose MAF ranges from 0.004 to 0.027 depending on the reference population. These variants are important to transfusion medicine but would not be available in any array design unless specifically targeted.
In addition to known variants, low-MAF variants are covered in high density among gene regions that may have transfusion implications. This design empowers the discovery of causal variants, even for the ones with low MAF, for transfusion medicine endpoints. Specifically, the array included variants designed to tag CNPs in the RHD region, which genetically determined a subject's D typing in high concordance with serology results. Additionally, a commercialized Axiom HLA module that provides 2-and 4-digit resolution, with 4-digit resolution accuracy of 88.6% to 98.4%, 49 was integrated into the array design because HLA antigens and antibodies are known to cause some adverse transfusion outcomes. 50 Recent studies have also shown that mitochondrial genetics may be responsible for some transfusion outcomes. 51, 52 Therefore, a mitochondrial module of 472 SNPs was also integrated into the design of the TMArray.
Although the TM-Array was carefully designed and tailored for transfusion medicine, there is room for further refinement. First, multiallelic markers were incorporated into the design of the array. However, we have not yet been able to perform a reliable global genotype calling for those multiallelic markers. A few important multiallelic variants were called manually using ad hoc methodologies through examination of the clustering plot and signal intensity, but the majority of multiallelic markers in the array have been excluded from analyses to date. Excluding these multiallelic markers would free up space for any additional content on the TM-Array. Second, variants for the GWAS booster were selected using 1000 Genomes Phase 1 release as the reference population. Imputation coverage for both East Asian and African American were higher than our design (Table 2 ) when using the 1000G_p3 release as imputation reference, notably a boost from 91% in design to over 97% for African American, because of the overrepresentation of the populations added in the reference. Future redesigning the GWAS booster based on 1000G_p3 may free up space for populations not specifically targeted by this array, such as South Asians and Native Americans, or to further boost overall imputation coverage. Third, the 12 probes designed to capture HbS and HbC variants that are 1 bp apart achieved only a 93% to 96% concordance rate, suggesting the current design is not yet suitable for classification of SCD genotypes in clinical settings. However, as shown in Fig. S1 , array technology is capable of distinguishing two clinically significant variants by adding signal intensity to the genotype clustering; thus, it is suitable as an alternative low-cost and high-throughput screening method, although further refinement of the design and development of genotype calling algorithms would be necessary. This array shared a common GWAS grid backbone with the UK Biobank Array, which was employed in the UK Interval Study of blood donors to investigate factors relevant to safe donation frequency, donor complications, and health outcomes.
14 This makes it possible to combine data for imputation. The TM-Array provided over 96% genome-wide coverage for African American, Hispanic, and white populations and over 94% for Asians. This not only enables genomics profiling of minority (and majority) populations at scale, but also makes it suitable for genotyping admixture populations of both blood donors and transfusion recipients. Although it is generally believed that racial and ethnic differences between a donor and a recipient do not impact transfusion outcome(s), donor genetics likely impact RBC storage properties 39, 40 and potentially RBC transfusion efficacy, and mismatches of genetic variants between a donor and cognate recipient as a result of differing haplotype background might contribute to undesirable outcomes. For example, in patients with SCD, who often require chronic blood transfusion, induction of alloantibodies from exposure to genetically dissimilar RBCs complicates their future blood group matching. 53, 54 Using a single platform for transfusion medicine-related GWAS will make experimental design easier for the investigation of potential risk factors or to adjust for any variants in statistical tests. Additionally, recent studies have shown that transethnic meta-analyses increase the power to detect novel loci and improve resolution of fine mapping, not only through increased sample size but also by leveraging differences in local linkage disequilibrium structure between ethnic groups. 55, 56 In addition to being used in hypothesis generation studies such as GWAS, the array can be used in a diverse set of transfusion medicine-related studies. Because it is constructed to be broadly informative across diverse populations, it can be applied to study sickle cell anemia even in a racially mixed population such as in the Brazil SCD cohort. The INTERVAL trial, 28 
CONCLUSIONS
The TM-Array is performing well, with over 99% of SNPs being called across 13,168 blood US donors in the REDS-III/ RBC-Omics study and 2700 Brazilian patients in the REDS-III Brazil SCD cohort. Individually, 99.8% of samples have greater than 95% of SNPs being called. Of the biallelic SNPs, 95.2% (833,872 of 875,837) are being called with high confidence; this includes the ability to type rare markers accurately. The TM-Array is a powerful tool for studying bloodand transfusion-related disorders in many ethnic groups. The array has produced high-quality genotype calls across the first 16,000 individuals screened. The number of genotypes per sample called is high, and genotype calling is accurate. We have allowed the content of this array to be made available to the wider community as a commercially available tool that is supported for quality control/quality assurance by the manufacturer (Thermo Fisher Scientific). Most of the genotyped data will become available through dbGaP. 
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article. Fig. S1 . Raw signal intensity plot of one of the 12 probes designed to capture the HbS/C mutation. Each dot represents one patient. Clinically determined SCD types were shown in different colors. SS is pink and SC is light blue. Plot shows the clustering of HbSS and HbSC patients. TABLE S1. Full list of blood group variants included in the array design. Each variant is labeled with nucleotide change nomenclature, Reference SNP cluster ID (rsID), chromosome number and physical location, and reference and alternative alleles..
